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Abstract
Frizzled homolog 3 receptor was up-regulated in several gastrointestinal cancers such as esophageal and gastric
cancers. Moreover, frizzled homolog 3 has recently reported to be expressed in colorectal adenoma specimens. In
the present study, we investigated the clinical significance of frizzled homolog 3 protein in colorectal cancer patients.
Using immunocytochemical staining, frizzled homolog 3 expression was examined in 186 colorectal cancer
specimens, 79 colorectal adenoma specimens, 133 colorectal polyp specimens, 127 colorectal cancer specimens
with lymph node and/or distant metastasis, 310 specimens of various non-colorectal cancer metastatic carcinomas
and 40 specimens with simultaneous occurrence of colorectal cancer, colorectal adenoma and colorectal polyp.
Statistical analysis was used to correlate frizzled homolog 3 protein expression to the clinicohistopathological factors,
recurrence/metastasis and survival after follow-up for 42 months in colorectal cancer patients. Frizzled homolog 3
protein was expressed in 100% colorectal cancer specimens, 89% colorectal adenoma specimens, 75% colorectal
polyp specimens and 69% normal colorectal epithelial tissues. Moreover, frizzled homolog 3 immunocytochemical
scores were highly correlated with colorectal cancer progression. Furthermore, frizzled homolog 3 was expressed in
a comparatively lower percentage of metastatic hepatocellular carcinoma and metastatic renal clear cell carcinoma
with focal and very weak staining than other metastatic tumor types. On the other hand, the frizzled homolog 3
immunocytochemical scores of colorectal adenomas with synchronous colorectal carcinomas were significantly
higher than those of pure colorectal adenomas. Statistical analysis showed that frizzled homolog 3
immunocytochemical scores were associated with Dukes stage and lymph node status. Finally, stratified groups of
colorectal cancer patients had significant differences in their recurrence/metastasis and survival. In conclusion, the
present large-scale study has clearly showed that frizzled homolog 3 protein can generate clinically important
information for colorectal cancer patients.
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Introduction
Colorectal cancer (CRC) is the third most frequently
diagnosed cancer worldwide, accounting for more than 1
million cases and 600,000 deaths every year [1]. The
development of CRC is a multi-step process and this disease
can be managed if detected in its early stage when it is mostly
symptomless [2-4]. Despite considerable improvements in the
detection, diagnosis and treatment of CRC in the last few
decades, the long-term prognosis of metastatic CRC patients
remains poor [5,6]. Clinical evidence shows that the current
staging criteria which are based on clinical and pathologic
findings, although recently revised, do not reflect the variation
in prognosis and survival for metastatic CRC [7]. Therefore, an
accurate prognostic marker which 1) determines the biological
nature and behavior of CRC, and 2) reflects the survival
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differences and clinical experiences, would be of utmost
importance to optimize individual treatment of CRC patients.
Wnt factors comprise a large family of secreted glycoproteins
that participate in embryonic development by regulating tissue
patterning, organogenesis, specification of the body plan and
promote tissue homeostasis in the adult [8]. At the cellular
level, Wnt factors control proliferation, differentiation, survival,
motility and polarity [9]. Tight control of Wnt signaling is crucial
for the correct orchestration of development and aberrant
constitutive activation of the Wnt signaling pathway will lead to
uncontrolled cell proliferation, growth and survival, therefore
promoting the development of cancer [9]. Frizzled homolog
protein (FZD) is a seven-pass transmembrane type receptor
and ten members (FZD1-FZD10) have been identified in
humans [10]. Wnt is a ligand of FZDs and consists of 19 family
genes in humans [11]. The binding of Wnt ligands to their cell-
surface receptors transduces intracellular signals through
either canonical or non-canonical Wnt-signaling pathway. In the
canonical Wnt signaling pathway, Wnts bind to a complex of
FZD and low-density lipoprotein-related receptors 5 and 6
[12-14]. The resultant signals prevent β-catenin
phosphorylation by a multiprotein complex composed of
adenomatous polyposis coli, glycogen synthase kinase 3β,
casin kinase 1 and axins, and promote the stabilization of
cytosolic β-catenin which some of it will translocate into the
nucleus [12-14]. The nuclear β-catenin will associate with T-cell
factor /lymphocyte enhancer transcription factors to activate
target genes involved in cell survival, proliferation or invasion
[12-14]. The non-canonical Wnt signaling pathway consists of
the Wnt/Ca2+ pathway and Wnt/c-Jun N-terminal kinase (planar
cell polarity) pathway and Wnts bind to a complex comprised of
FZD, receptor tyrosine kinase-like orphan receptor 2/receptor
related to tyrosine kinase for activation of downstream
signaling [12-14]. In Wnt/Ca2+ pathway, Wnt activates
intracellular Ca2+ signaling, as well as Ca2+ - dependent protein
kinases, such as protein kinase C and calmodulin dependent
protein kinase II [12-14]. In the Wnt/JNK pathway, receptor
stimulation activates Dishevelled, which in turn activates the
Rho family of GTPases such as RhoA and Rac [12-14]. RhoA
stimulates c-Jun expression through phosphorylation of c-Jun
by Rho associated kinase [12-14]. In summary, FZD plays a
crucial role in both canonical and non-canonical pathways.
Human FZD3 was mapped to chromosome 8p21 [10,15].
FZD3 mRNA is expressed in various normal tissues (skeletal
muscle, kidney, pancreas, cerebellum and cerebral cortex) [10]
whereas it is up-regulated in several cancers (esophageal
carcinoma, lung squamous cell carcinoma, primary acute and
lymphoblastic leukemia, myeloma, lymphoma and Ewing
sarcoma) [16-19]. A recent report has shown that FZD3 mRNA
was expressed in a small cohort of sporadic adenoma and
familial adenomatous polyposis adenoma tissues [20]. The
significance of it is not known yet and therefore it will be
interesting to examine the expression of FZD3 protein in a
large cohort of primary and metastatic CRC samples and
colorectal adenoma (CAD) samples. The information obtained
will be very useful for us to examine the prognostic potential of
FZD3 protein in patients with CRC. In addition, the expression
of FZD3 protein in other types of metastatic cancers was also
examined in order to explore whether FZD3 protein can be
used as an adjunct diagnostic marker for metastatic CRC.
Materials and Methods
Ethics Statement
The study was conducted according to the principles
expressed in the Declaration of Helsinki. Written informed
consent was obtained from all patients or the next of kin for use
of those samples in research. Since patient consent was not
possible for archival tissues as some patients were deceased
at the time of study, the ethics committee specifically waived
the need for consent from those patients. The study was
approved by the Clinical Research Ethics Committee of the
Queen Elizabeth Hospital, Hong Kong Special Administrative
Region (HKSAR).
Tissue Specimens
Seven cohorts of formalin fixed, paraffin-embedded (FFPE)
specimens were recruited: 1) CRC with Dukes classification
system stage A (43), stage B (48), stage C (63), stage D (32),
total: 186, 2) CAD with mild dysplasia (25), moderate dysplasia
(28), severe dysplasia (26), total: 79, 3) colorectal polyp which
is specifically defined as non-adenomatous or non-neoplastic
polyps which consist of juvenile (35), hyperplastic (40), Peutz-
Jeghers (28) and inflammatory polyps (30), total: 133, 4) one
FFPE block with lymph node metastasis from each Dukes C
specimen, total: 63, 5) one FFPE block each with lymph node
and distant metastasis from each Dukes D specimen, total: 64,
6) three hundred and ten non-CRC metastatic carcinomas
which the primary tumor was respectively hepatocellular
carcinoma (HCC) (23), renal clear cell carcinoma (RCCC) (25),
squamous cell carcinoma (SCC1) (30), lung adenocarcinoma
(LAC) (25), lung non-small cell carcinoma (LNSCC) (27),
papillary thyroid carcinoma (PTC) (24), breast carcinoma (BC)
(28), ovary clear cell carcinoma (OCCC) (30), cervical non-
small cell carcinoma (CNSCC) (20), fallopian tube serous
adenocarcinoma (FTSAC) (22), transitional cell carcinoma
(TCC) (23), small cell carcinoma (SCC2) (15) and carcinoma
with neuroendocrine differentiation (CND) (18), 7) specimens
from forty CRC patients (10 Dukes A, 10 Dukes B, 12 Dukes C,
8 Dukes D) with simultaneous occurrence of CRC, adenoma
and polyp (120), were retrieved from the archives (2005-2008)
of the Anatomical Pathology and Cytology Laboratory,
Department of Pathology, Queen Elizabeth Hospital, HKSAR,
for FZD3 immunocytochemical (ICC) staining.
Most cases of the colorectal adenocarcinomas in the first
cohort were moderately differentiated (78%), whereas the rest
were either well differentiated (5%) or poorly differentiated
(17%). The sex distribution of adenocarcinoma patients was
58% male and 42% female. The age ranged from 42 to 89
years old. Of the 79 adenoma specimens examined in cohort 2,
59% was tubular, 35% was tubulovillous, and 6% was villous
adenomas. The percentages of mild, moderate, and severe
dysplasia in adenomas were 32, 35 and 33, respectively. The
sex distribution of adenoma patients was 53% male and 47%
female. The age ranged from 28 to 85 years old. The polyps
evaluated in cohort 3 were juvenile (26%), hyperplastic (30%),
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Peutz-Jeghers (21%), and inflammatory polyps (23%). Of the
133 polyps, the sex distribution was 51% male, 49% female
and the age ranged from 23 to 76 years old. The clinical
information of the patients with simultaneous occurrence of
CRC, adenomas and polyps in the seventh cohort were
moderately differentiated (75%), well differentiated (7%) or
poorly differentiated (18%). The sex distribution of
adenocarcinoma patients was 60% male and 40% female. The
age ranged from 45 to 87 years old.
Antibody
Monoclonal mouse anti-human FZD3 antibody (1:100
dilution, clone 169310, MAB1001, R&D Systems, Inc.,
Minneapolis, USA) was used.
ICC staining and evaluation
Serial tissue sections (4 μm thick) were cut and antigen
retrieval was performed using Bond Epitope Retrieval Solution
2 on the Bond-max automated immunostainer (Vision
BioSystems, Mount Waverley, Australia) at 100°C for 25
minutes. Staining was performed according to a standard
protocol in the immunostainer. Polymer detection system was
selected to avoid the problem of nonspecific endogenous biotin
staining. Esophageal carcinoma was used as a positive control
[16] which was mounted on every test slide and negative
controls were performed by replacing the antibody with tris
buffered saline. In order to measure the FZD3 expression in
each patient specimen accurately, a maximum number of
target cells with the staining intensity which reflects the general
expression pattern is the main criteria for scoring. The stained
slides were evaluated in at least 5 fields with the highest
number of target cells under light microscope at X400
magnification by 2 independent observers without knowledge
of clinical outcomes and in the case of disagreement,
consensus was reached after thorough discussion and slides
examination using a multi-headed microscope. Approximately
250 cells would be counted in each field and therefore at least
1,250 cells would be counted for each patient specimen. All
slides were scored semi-quantitatively and expressed as an
ICC score by multiplying the “percentage of positive cells” and
the “staining intensity”, as described previously [21]. Staining
intensity was scored as follows: 0 = negative; 1 = weak; 2 =
moderate; 3 = strong; and 4 = very strong. The ICC score
ranged from 0 to 400. The scoring of percentage and staining
intensity was targeted to 1) CRC cells, 2) CAD cells and 3)
adjacent normal epithelial cells. Membranous staining should
be the expected result. However, our experience showed that
ICC staining using diaminobenzidine as chromogen would
produce a thickened membranous staining which was similar to
cytoplasmic staining. Besides, the antibody used in this study
had the best performance among the antibodies which had
been tested.
Statistical analysis
The difference in ICC scores of FZD3 protein among CRC,
CAD and adjacent normal colorectal epithelial cells was studied
using non-parametric Kruskal-Wallis test. In addition, non-
parametric Spearman rank correlation test was used to
examine whether FZD3 ICC scores were correlated with CRC
progression and Dukes classification stages. Mann Whitney U
test was used to examine whether the ICC scores of CAD with
synchronous colorectal carcinomas had significant difference
from those of pure CAD. For correlation to clinical parameters,
multivariate regression was used to analyze whether FZD3 ICC
scores were correlated with the clinico-histopathological factors
of the patients and chi-square test was used to examine the
association between FZD3 ICC scores and recurrent or
metastatic CRC. The overall survival was defined as that from
the date of the operation to the date of death due to cancer.
The Kaplan-Meier method was used to determine the
probability of survival and log-rank test was used to compare
the survival between the groups and Cox proportional hazards
model was applied to determine the independent prognostic
factors of survival. (Statistical Package for the Social Sciences
Version 16.0 software for Windows, IBM SPSS statistics,
Chicago, IL., USA). A P value < 0.05 was considered to be




As mentioned in the ICC staining and evaluation section, a
thickened membranous staining which resembled cytoplasmic
staining was detected. Among the 955 slides that we have
examined, inter-individual variation was found only in 16 slides
(1.7%) and consensus was reached after discussion using a
multi-headed microscope.
ICC staining showed that FZD3 protein was expressed in
100% (186/186) of CRC specimens, 89% (70/79) of CAD
specimens, 75% (100/133) of colorectal polyp specimens and
69% (129/186) of normal colorectal epithelial tissues adjacent
to CRC tissues. A representative photomicrograph of each
specimen type in the first cohort was shown in Figure 1.
Positive control of esophageal carcinoma showed intense
positive cytoplasmic staining whereas negative control did not
have any ICC staining (Figures 1E and 1F). Detailed analysis
showed that the immunoreactivity of FZD3 protein, as shown
by the ICC scores, had significant difference among CRC,
CAD, colorectal polyp and normal colorectal epithelial tissues
(Figure 2, P < 0.0001, Kruskal-Wallis test) and the range and
median of the ICC scores in various specimen types were
shown in Table 1. FZD3 ICC scores were highly correlated with
the stages of progression of CRC (P < 0.0001, Spearman rank
correlation test). Moreover, the ICC scores of FZD3 protein in
CRC specimens was significantly correlated with Dukes stage
(Figure 3, P < 0.0001, Spearman rank correlation test).
Furthermore, our findings showed that FZD3 protein was
expressed in 100% metastatic CRC cells in lymph nodes
or/and distant organs from Dukes 3 and 4 specimens,
respectively (Figure 4). In line with those results, we continued
to examine whether FZD3 can be used as an adjunct
diagnostic marker for metastatic CRC by performing FZD3 ICC
staining in 310 non-CRC metastatic carcinoma specimens.
Results showed that FZD3 protein was expressed in 17%
(4/23) of HCC, 12% (3/25) of RCCC, 80% (24/30) of SCC1,
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84% (21/25) of LAC, 82% (22/27) of LNSCC, 88% (21/24) of
PTC, 86% (24/28) of BC, 80% (24/30) of OCCC, 85% (17/20)
of CNSCC, 82% (18/22) of FTSAC, 74% (17/23) of TCC, 100%
(15/15) of SCC2 and 100% (18/18) of CND (Figures 5A and
5B). In cases with positive results, detailed examination
showed that the staining was focal and very weak in HCC,
RCCC when compared to those in other tumor types (Figures
5B and 6).
Similar observations were found for specimens with
simultaneous occurrence of colorectal carcinoma, CAD and
colorectal polyp. ICC staining for FZD3 was observed in 100%
(40/40) of CRC, 93% (37/40) of CAD, 70% (28/40) of colorectal
polyp. Moreover, FZD3 ICC scores were highly correlated with
the stages of progression of CRC (P < 0.0001, Spearman rank
correlation test). Of interest, the ICC scores of CAD with
synchronous colorectal carcinomas were significantly higher
than those of pure CAD (P < 0.001, Mann Whitney U test,
Figure 7).
Multivariate regression analysis
Multivariate regression analysis was applied to examine
whether FZD3 ICC scores were correlated with the
clinicohistopathological factors of the 186 Dukes A to D CRC
patients. Significant associations were found with Dukes stage
(P < 0.001) and lymph node status (P < 0.05) but not for age (P
= 0.547), sex (P = 0.813), tumor stage (P = 0.284) and degree
of differentiation (P = 0.462).
Recurrent or metastatic CRC
The median number of FZD3 ICC scores from the 154 Dukes
A to C CRC patients was 321.5. Using this median number as
the cut-off point, 27 patients with FZD3 ICC score > 321.5 and
8 patients with FZD3 ICC score ≤ 321.5 had recurrent or
metastatic CRC after follow-up for 42 months and the
association between FZD3 ICC scores and recurrent or
metastatic CRC was highly significant (Chi-square test: χ2 =
13.34; P < 0.001).
Overall survival of CRC patients
Overall survival curves were plotted for CRC patients with
FZD3 ICC scores > 327 and those with FZD3 ICC scores ≤ 327
where 327 is the median number of FZD3 ICC scores from the
1st cohort of 186 Dukes A to D CRC patients. Our results
showed that the survival for those 2 groups of patients was
significantly different (P < 0.0001, log-rank test, Figure 8A). In
order to analyse the data in a more specific manner, the FZD3
ICC scores were divided into 4 groups after aligning it in
descending order: 1) high FZD3 expression: highest 25% (76%
to 100%) ICC scores, 2) moderately high FZD3 expression:
second highest 25% (51% to 75%) ICC scores, 3) moderately
low FZD3 expression: second lowest 25% (26% to 50%) ICC
scores and 4) low FZD3 expression: lowest 25% (0% to 25%)
ICC scores. As shown in Figures 8B and 8C, the survival
between groups 1 and 4 and groups 2 and 3 were significant (P
< 0.0001 for A vs D and P < 0.05 for B vs C, log-rank test).
Finally, the independent prognostic factors of overall survival
identified by the Cox proportional hazards regression model
were found to be FZD3 ICC score (P = 0.016) and lymph node
status (P = 0.037).
Discussion
FZD3 is a receptor for the Wnt-signaling pathway and FZD3
protein is required for the development of major fiber tracts in
the rostral central nervous system [22], neural crest [23] and
hair follicle development [24]. Moreover, FZD3 protein has a
predominant role in Wnt-induced neurite outgrowth in Ewing
sarcoma tumor cells [25] and it is highly expressed in poorly
differentiated squamous cell esophageal carcinoma tissues
[16]. To the best of our knowledge, this study is the first to
examine the clinical significance of FZD3 protein expression in
a large cohort of CRC and its pre-malignant CAD and
colorectal polyp specimens. Despite the fact that FZD3 protein
was expressed in 100% of CRC specimens, 89% of CAD
specimens, 75% of colorectal polyp specimens and 69%
adjacent normal colorectal epithelial tissues, the
immunoreactivity of FZD3 had significant difference among
those 4 groups of specimens. Moreover, FZD3 protein
expression in CAD as shown by us matches with those of a
previous study that FZD3 mRNA expressed in 79% (11/14)
CAD specimens with a median fold change of 6.5 [26].
However, FZD3 mRNA was only found to have a significant up-
regulation in 39% (9/23) CRC specimens in the same study
[26]. The reasons account for this conflicting result can be
explained by the following reasons: 1) a small number (23) of
CRC specimens were recruited as compared to ours, 2) mRNA
was detected whereas protein was detected in our study, 3)
adjacent normal tissues were mixed with the CRC tissues as
no microdissection was performed in their study. The last point
is especially significant because variable degrees of adjacent
normal tissues will usually be found in surgical specimens and
our findings showed that FZD3 protein was expressed not only
in 69% of adjacent normal colorectal epithelial tissues, but also
in fibroblasts, endothelial cells, lymphocytes and histiocytes
(data not shown). ICC staining of a tissue section allows us to
examine the individual cell under microscope and therefore the
FZD3 protein expression in tumor and normal cells can be
separately quantified. In reality, the ICC staining of FZD3
protein was not only stronger in the invasive front than in the
tumor center but also very intense in all metastatic lymph
nodes and distant organs. This remarkable finding can show
that FZD3 protein has an important role not only in early CRC
carcinogenesis, but also in CRC metastatic pathway to lymph
nodes and distant organs. However, focal polarized distribution
of FZD3 as shown by Pourreyron et al. was not found in our
cohort of specimens [27]. We continued to investigate the
potential of FZD3 protein as an adjunct diagnostic marker in
metastatic CRC by performing ICC staining in various types of
non-CRC metastatic carcinomas. Our results are very
interesting because ICC staining for FZD3 was positive to
various extents in all metastatic carcinomas. However, the
positive staining in only 17% of HCC and 12% of RCCC shows
that FZD3 protein may not be so essential in the metastatic
process of those 2 carcinomas (Figures 5A and 5B). In
summary, FZD3 ICC staining may be helpful to exclude those 2
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Figure 1.  ICC staining of FZD3 in (A) CRC, (B), CAD, (C) colorectal polyp, (D) normal colorectal tissues, (E) positive
control and (F) negative control (Original magnification, X400, scale bar = 100 µm).  
doi: 10.1371/journal.pone.0079481.g001
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carcinomas upon pathological diagnosis because the staining
was focal and very weak in those FZD3 staining positive HCC
and RCCC cases when compared to those in other tumor
types. On the other hand, FZD3 protein was expressed in
metastatic carcinomas which include SCC1, LAC, LNSCC,
PTC, BC, OCCC, CNSCC, FTSAC, TCC, SCC2 and CND.
Those novel results can show that FZD3 protein may be
involved in the metastatic process of those carcinomas. In fact,
the strong staining of FZD3 protein in all cases of CND and
SCC2 is not surprising because FZD3 protein is well known to
be involved in central nervous system development [22,23,28].
In line with those results, we are currently examine the FZD3
protein expression in their respective primary tumors for those
11 types of metastatic non-CRC carcinomas which have high
level of FZD3 protein expression in order to have a more
understanding on the role of FZD3 protein in various
carcinogenesis pathways.
Another interesting finding from this study is that the median
ICC score of the CAD associated with synchronous colorectal
carcinomas is much higher than that of the group consisting of
pure CAD, suggesting that a high FZD3 protein expression in
CAD may signify a higher malignancy potential.
The ultimate goal of this study is to explore the clinical
significance of FZD3 protein in patients with CRC. As currently
there is scanty pathologically used prognostic marker for CRC
and therefore it is invaluable to investigate the prognostic
potential of FZD3 protein which is demonstrated in this study
by the significant correlation of FZD3 ICC scores to Dukes
stage, lymph node status, recurrence or metastasis. Moreover,
a long-term follow-up of those CRC patients showed that
patient with a high FZD3 ICC score may have a less chance of
survival. Actually, the specimens with FZD3 ICC scores > 327














specimens 186 79 133 186
Range of ICC
scores 243 to 400 0 to 347 0 to 360 0 to 279
Median ICC
scores 327 241 192 97.5
doi: 10.1371/journal.pone.0079481.t001
Figure 2.  ICC scores of FZD3 in (A) CRC, (B) CAD, (C) colorectal polyp and (D) normal colorectal tissues.  
doi: 10.1371/journal.pone.0079481.g002
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were mainly of stages III and IV patients whereas those with
FZD3 ICC scores ≤ 327 were mostly of stages I and II patients.
This may be one explanation why stages III and IV patients
have a greater risk of recurrence, metastasis and shorter
survival than stages I and II patients. A more detailed analysis
of the data by classifying it into 4 groups based on their level of
expression can provide us more information on the prognostic
significance of FZD3 protein in CRC patients. The significant
difference in survival between high and low expression groups
is expected whereas the marginal significant difference (P <
Figure 3.  ICC scores of FZD3 in various Dukes stage of patients with CRC.  
doi: 10.1371/journal.pone.0079481.g003
Figure 4.  ICC staining of FZD3 in (A) a lymph node with CRC metastasis from a Dukes 3 patient and (B) an ovary with
CRC metastasis from a Dukes 4 patient (T = tumor, Lym = lymphoid cells, original magnification, X400, scale bar = 100
µm).  
doi: 10.1371/journal.pone.0079481.g004
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Figure 5.  FZD3 expression in various non-CRC metastatic carcinomas.  (A) Percentage of various non-CRC metastatic
carcinomas with FZD3 ICC staining and (B) ICC scores of FZD3 in various non-CRC metastatic carcinomas. (HCC = hepatocellular
carcinoma, RCCC = renal clear cell carcinoma, SCC1 = squamous cell carcinoma, LAC = lung adenocarcinoma, LNSCC = lung
non-small cell carcinoma, PTC = papillary thyroid carcinoma, BC = breast carcinoma, OCCC = ovary clear cell carcinoma, CNSCC
= cervical non-small cell carcinoma, FTSAC = fallopian tube serous adenocarcinoma, TCC = transitional cell carcinoma, SCC2 =
small cell carcinoma and CND = carcinoma with neuroendocrine differentiation).
doi: 10.1371/journal.pone.0079481.g005
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0.05) in survival between moderately high and moderately low
expression groups provides a solid evidence that FZD3 protein
has important prognostic power. Taken all those findings
together, FZD3 ICC staining can potentially be a valuable tool
for the prognosis of CRC. In order to validate those findings, a
large multi-centre trial with a long-term follow-up on examining
its prognostic significance is now being prepared. Human
Wnt5A, Wnt5B and Wnt11 are representative non-canonical
Wnts transducing Wnt/planar cell polarity signals through FZD3
receptors [10,29-31]. A recent study has shown that Wnt
response pathways were re-organized in early colorectal
carcinogenesis as the negative regulator of Wnt signaling
Figure 6.  ICC staining of FZD3 in (A) a metastatic hepatocellular carcinoma and (B) a metastatic renal clear cell
carcinoma (Original magnification, X400, scale bar = 100 µm).  
doi: 10.1371/journal.pone.0079481.g006
Figure 7.  ICC scores of FZD3 in (A) adenomas with synchronous carcinomas (AWSC) and (B) pure adenomas.  
doi: 10.1371/journal.pone.0079481.g007
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Figure 8.  Overall survival analyses for the 1st cohort of 186 Dukes A to D CRC patients (A) stratified by a median FZD3
ICC score of 327, (B) with high and low FZD3 expression and (C) with moderately high and moderately low FZD3
expression.  
doi: 10.1371/journal.pone.0079481.g008
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pathway, naked cuticle homologue 1 induction was
accompanied by up-regulation of the β-catenin-independent
FZD3 receptor in CAD and CRC [26]. Moreover, FZD3 did not
respond to stabilization of β-catenin in vitro and required a Wnt
ligand signal [26]. Therefore, FZD3 may provide an indication
of the degree of Wnt ligand signaling in the colorectal tumor. In
fact, a small cohort of specimens (20) with strong and weak
positive FZD3 were recruited and a direct comparison of FZD3
immunostaining to those of beta-catenin were performed and it
was found that there was no correlation between FZD3 and
beta-catenin immunostaining (data not shown). This finding can
strengthen the role of FZD3 in non-canonical Wnt signaling
pathway. Together with the results from this study, the
expression of FZD3 protein in various clinical stages of CRC
can further demonstrate the clinical significance of FZD3 in
patients with CRC. Our next step is to examine the underlying
molecular mechanisms that regulate FZD3 expression and the
direct transcriptional target genes of FZD3 using specific
knockdown of FZD3 by small interfering RNA in CRC cell lines
because targeted therapy using molecular markers is an
important goal for improving the outcomes of patients with
CRC. Furthermore, the detection of FZD3 protein in patient’s
serum using enzyme-linked immunosorbent assay will also be
explored in order to assess whether serum FZD3 protein can
be used as a non-invasive marker. However, a major limitation
of this study is that we do not have the clinical information to
assess the performance of FZD3 protein by comparing its
expression to conventional CRC marker such as serum
carcinoembryonic antigen.
In summary, FZD3 protein expression as shown by ICC
staining is closely correlated with colorectal carcinogenesis and
progression, and can potentially serve as a new prognostic
marker. Moreover, FZD3 ICC staining may be helpful to
exclude HCC and RCCC in metastatic sites.
Acknowledgements
We are grateful to Professor Benjamin Y.M. Yung and Mr. Chiu
Ka Yue for their outstanding support.
Author Contributions
Conceived and designed the experiments: SCCW CMLC
BBYM ATCC. Performed the experiments: CWH AKCC HTW
TCCA MKC. Analyzed the data: SCCW MTC LLYL.
Contributed reagents/materials/analysis tools: SCCW AKCC
HTW MTC LLYL. Wrote the manuscript: SCCW CWH.
References
1. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR et al. (2010)
Once-only flexible sigmoidoscopy screening in prevention of colorectal
cancer: a multicentre randomised controlled trial. Lancet 375:
1624-1633. doi:10.1016/S0140-6736(10)60551-X. PubMed: 20430429.
2. Traverso G, Shuber A, Olsson L, Levin B, Johnson C et al. (2002)
Detection of proximal colorectal cancers through analysis of faecal
DNA. Lancet 359: 403-404. doi:10.1016/S0140-6736(02)07591-8.
PubMed: 11844514.
3. Schoen RE (2002) The case for population-based screening for
colorectal cancer. Nat Rev Cancer 2: 65-70. doi:10.1038/nrc705.
PubMed: 11902587.
4. Wong SC, Lo SF, Cheung MT, Ng KO, Tse CW et al. (2004)
Quantification of plasma beta-catenin mRNA in colorectal cancer and
adenoma patients. Clin Cancer Res 10: 1613-1617. doi:
10.1158/1078-0432.CCR-1168-3. PubMed: 15014011.
5. Davies RJ, Freeman A, Morris LS, Bingham S, Dilworth S et al. (2002)
Analysis of minichromosome maintenance proteins as a novel method
for detection of colorectal cancer in stool. Lancet 359: 1917-1919. doi:
10.1016/S0140-6736(02)08739-1. PubMed: 12057556.
6. Wong SC, Chan CM, Ma BB, Hui EP, Ng SS et al. (2009) Clinical
significance of cytokeratin 20-positive circulating tumor cells detected
by a refined immunomagnetic enrichment assay in colorectal cancer
patients. Clin Cancer Res 15: 1005-1012. doi:
10.1158/1078-0432.CCR-08-1515. PubMed: 19188172.
7. Edge SB, American Joint Committee on Cancer (2010) AJCC cancer
staging manual. xiv. New York: Springer Verlag. 648 pp.
8. Wodarz A, Nusse R (1998) Mechanisms of Wnt signaling in
development. Annu Rev Cell Dev Biol 14: 59-88. doi:10.1146/
annurev.cellbio.14.1.59. PubMed: 9891778.
9. Polakis P (2012) Drugging Wnt signalling in cancer. EMBO J 31:
2737-2746. doi:10.1038/emboj.2012.126. PubMed: 22617421.
10. Kirikoshi H, Koike J, Sagara N, Saitoh T, Tokuhara M et al. (2000)
Molecular cloning and genomic structure of human frizzled-3 at
chromosome 8p21. Biochem Biophys Res Commun 271: 8-14. doi:
10.1006/bbrc.2000.2578. PubMed: 10777673.
11. Moon RT, Brown JD, Torres M (1997) WNTs modulate cell fate and
behavior during vertebrate development. Trends Genet 13: 157-162.
doi:10.1016/S0168-9525(97)01093-7. PubMed: 9097727.
12. Sethi JK, Vidal-Puig A (2010) Wnt signalling and the control of cellular
metabolism. Biochem J 427: 1-17. doi:10.1042/BJ20091866. PubMed:
20226003.
13. Clevers H (2006) Wnt/beta-catenin signaling in development and
disease. Cell 127: 469-480. doi:10.1016/j.cell.2006.10.018. PubMed:
17081971.
14. Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004) WNT and beta-
catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701.
doi:10.1038/nrg1427. PubMed: 15372092.
15. Sala CF, Formenti E, Terstappen GC, Caricasole A (2000)
Identification, gene structure, and expression of human frizzled-3
(FZD3). Biochem Biophys Res Commun 273: 27-34. doi:10.1006/bbrc.
2000.2882. PubMed: 10873558.
16. Tanaka S, Akiyoshi T, Mori M, Wands JR, Sugimachi K (1998) A novel
frizzled gene identified in human esophageal carcinoma mediates APC/
beta-catenin signals. Proc Natl Acad Sci U S A 95: 10164-10169. doi:
10.1073/pnas.95.17.10164. PubMed: 9707618.
17. Lee EH, Chari R, Lam A, Ng RT, Yee J et al. (2008) Disruption of the
non-canonical WNT pathway in lung squamous cell carcinoma. Clin.
Med Oncol: 2008: 169-179
18. Khan NI, Bradstock KF, Bendall LJ (2007) Activation of Wnt/beta-
catenin pathway mediates growth and survival in B-cell progenitor
acute lymphoblastic leukaemia. Br J Haematol 138: 338-348. doi:
10.1111/j.1365-2141.2007.06667.x. PubMed: 17614820.
19. Qiang YW, Endo Y, Rubin JS, Rudikoff S (2003) Wnt signaling in B-cell
neoplasia. Oncogene 22: 1536-1545. doi:10.1038/sj.onc.1206239.
PubMed: 12629517.
20. Caldwell GM, Jones CE, Ashley AM, Wei W, Hejmadi RK et al. (2010)
Wnt signalling in adenomas of familial adenomatous polyposis patients.
Br J Cancer 103: 910-917. doi:10.1038/sj.bjc.6605790. PubMed:
20628379.
21. Wong SC, Lo SF, Lee KC, Yam JW, Chan JK et al. (2002) Expression
of frizzled-related protein and Wnt-signalling molecules in invasive
human breast tumours. J Pathol 196: 145-153. doi:10.1002/path.1035.
PubMed: 11793365.
22. Wang Y, Thekdi N, Smallwood PM, Macke JP, Nathans J (2002)
Frizzled-3 is required for the development of major fiber tracts in the
rostral CNS. J Neurosci 22: 8563-8573. PubMed: 12351730.
23. Deardorff MA, Tan C, Saint-Jeannet JP, Klein PS (2001) A role for
frizzled 3 in neural crest development. Development 128: 3655-3663.
PubMed: 11585792.
24. Hung BS, Wang XQ, Cam GR, Rothnagel JA (2001) Characterization
of mouse Frizzled-3 expression in hair follicle development and
identification of the human homolog in keratinocytes. J Invest Dermatol
116: 940-946. doi:10.1046/j.1523-1747.2001.01336.x. PubMed:
11407985.
Clinical Significance of FZD3 in CRC Patients
PLOS ONE | www.plosone.org 11 November 2013 | Volume 8 | Issue 11 | e79481
25. Endo Y, Beauchamp E, Woods D, Taylor WG, Toretsky JA et al. (2008)
Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells
via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism.
Mol Cell Biol 28: 2368-2379. doi:10.1128/MCB.01780-07. PubMed:
18212053.
26. Caldwell GM, Jones CE, Soon Y, Warrack R, Morton DG et al. (2008)
Reorganisation of Wnt-response pathways in colorectal tumorigenesis.
Br J Cancer 98: 1437-1442. doi:10.1038/sj.bjc.6604327. PubMed:
18414471.
27. Pourreyron C, Reilly L, Proby C, Panteleyev A, Fleming C et al. (2012)
Wnt5a is strongly expressed at the leading edge in non-melanoma skin
cancer, forming active gradients, while canonical Wnt signalling is
repressed. PLOS ONE 7: e31827. doi:10.1371/journal.pone.0031827.
PubMed: 22384081.
28. Tan C, Deardorff MA, Saint-Jeannet JP, Yang J, Arzoumanian A et al.
(2001) Kermit, a frizzled interacting protein, regulates frizzled 3
signaling in neural crest development. Development 128: 3665-3674.
PubMed: 11585793.
29. Tokuhara M, Hirai M, Atomi Y, Terada M, Katoh M (1998) Molecular
cloning of human Frizzled-6. Biochem Biophys Res Commun 243:
622-627. doi:10.1006/bbrc.1998.8143. PubMed: 9480858.
30. Kirikoshi H, Sekihara H, Katoh M (2001) Expression profiles of 10
members of Frizzled gene family in human gastric cancer. Int J Oncol
19: 767-771. PubMed: 11562753.
31. Katoh M (2005) WNT/PCP signaling pathway and human cancer
(review). Oncol Rep 14: 1583-1588 PubMed: 16273260.
Clinical Significance of FZD3 in CRC Patients
PLOS ONE | www.plosone.org 12 November 2013 | Volume 8 | Issue 11 | e79481
